Jusvinza, promising med to fight Covid-19
Amid the encouraging news about the start of the first stage of post-covid-19 recovery last Thursday in most Cuban provinces, the Center for State Control of Medicines, Equipment and Medical Devices (CECMED) published the authorization of the emergency use of CIGB-258, called Jusvinza, for the treatment of COVID-19.
The news is extremely encouraging, considering that achieving a vaccine capable of fighting Covid-19 has a somewhat distant future. Jusvinza is a therapeutic alternative that controls hyperinflammation, regulating the immune response and reducing the risk of mortality in patients with the new coronavirus.
The information was released by the Cuban Biotechnology and Pharmaceutical Industries Group (BioCubaFarma) in social media. Previously, about four weeks ago, it was announced at the daily press conference on the pandemia situation in the country, that the application of that drug in 52 patients had been highly effective and had achieved a survival rate of 78 percent of critically ill patients.
On the other hand, 92 per cent of patients treated with Jusvinza managed to survive in seriously ill patients, a very encouraging rate when one considers that the average survival rate for seriously ill patients in the world is 20 per cent.
The results achieved have sparked interest in its use by several countries, so the authorization released will allow clinical trials to be carried out in the states that have requested it, and if similar results are obtained to those achieved in Cuba, the Jusvinza could form part of the action protocols in those nations, significantly contributing to reducing lethality.
Gillian Martínez Donato, CIGB researcher and manager of that project explained that the CIGB-258 or “Jusvinza” was designed to essentially activate the mechanisms that control and reduce inflammatory processes, hence its effectiveness in the fight against Covid-19.